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OBJECTIVES We sought to examine the importance of mutations in the cardiac transcription factor gene
NKX2-5 in patients with an atrial septal defect (ASD), patent foramen ovale (PFO), or
hypoplastic left heart syndrome (HLHS).
BACKGROUND Mutations in NKX2-5 have been found in families showing secundum ASD and atrioven-
tricular (AV) conduction block and in some individuals with tetralogy of Fallot. The
prevalence of NKX2-5 mutations in sporadic cases of ASD/PFO and other forms of
congenital heart disease is unknown.
METHODS A cohort of 146 individuals with secundum ASD, PFO complicated by paradoxical
embolism, or HLHS were evaluated. Patients with ASD or PFO were ascertained irrespective
of family history or associated cardiac abnormalities. The coding region of the NKX2-5 locus
was amplified by polymerase chain reaction and sequenced.
RESULTS Among 102 ASD and 25 PFO patients screened, 13 patients (10%) had a positive family
history and 5 patients (4%) had AV conduction block. We found one previously documented
NKX2-5 missense mutation, T178M, in members of a family with ASD without AV
conduction block. One NKX2-5 mutation-positive child from this family had HLHS,
although no mutations were subsequently found in 18 patients with sporadic or familial
HLHS. In a second ASD family without AV conduction block, we found a missense change,
E21Q, previously reported as pathogenic. Because this change did not segregate with disease
status, we propose that it is a non-disease–causing polymorphism.
CONCLUSIONS Our findings suggest that NKX2-5 mutations are a relatively infrequent cause of sporadic
ASD and HLHS. Screening for NKX2-5 mutations may be warranted in individuals with
ASD and a positive family history, irrespective of the presence or absence of AV conduction
block. (J Am Coll Cardiol 2003;41:2072–6) © 2003 by the American College of
Cardiology Foundation
The secundum atrial septal defect (ASD) accounts for
10% of congenital cardiac malformations (1). Large ASDs
can lead to cardiac failure in childhood, but the morbidity
associated with untreated ASD is largely due to the devel-
opment of pulmonary hypertension with right heart dilation
and atrial arrhythmia in later life. In adults, percutaneous
closure techniques are being increasingly used as an alter-
native to surgery to prevent ASD complications.
The ASD is causally heterogeneous. Population-based
studies suggest that ASD is multifactorial in origin, but with
a strong genetic component, and estimates of heritability are
in the order of 0.6 to 0.7, similar to figures for congenital
heart disease (CHD) in general (1). It can occur in mono-
genic familial conditions, sometimes in association with
other cardiac malformations, or as one feature of syndromes,
although most cases appear sporadic. The ASD has also
been associated with in utero exposure to teratogens such as
alcohol.
Recently, mutations in the cardiac homeobox transcrip-
tion factor gene NKX2-5 (or CSX1) have been found in
families with inherited autosomal-dominant ASD and
atrioventricular (AV) conduction block (2– 4). Eleven
disease-associated mutations have been documented to date.
Other congenital heart abnormalities have been observed at
low penetrance in these families, including the ventricular
septal defect, Ebstein’s anomaly, tetralogy of Fallot (TOF),
subvalvular aortic stenosis, and tricuspid valve abnormality
(2,3). A survey of patients with nonsyndromic TOF also
identified NKX2-5 mutations in 4% of individuals, in-
cluding three new mutations (5). In mice, heterozygous
loss-of-function NKX2-5 mutations lead to a mild conduc-
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tion delay and atrial septal dysmorphogenesis manifest as an
increased frequency of patent foramen ovale (PFO), atrial
septal aneurysm, and ASD (6). The higher penetrance of
ASD and conduction disease in humans, as compared with
mice, may reflect genetic background (6) or the dominant-
negative nature of human mutations (7).
It is currently unknown to what extent dominant or
modifying NKX2-5 mutations contribute to sporadic or
familial CHD. Here, we examined whether NKX2-5 mu-
tations play an important role in the causation of ASD and
PFO in individuals unselected for a family history or AV
conduction abnormalities. Accordingly, we sequenced the
coding region of NKX2-5 in a cohort of 102 ASD and 25
PFO patients ascertained only by their requirement for
septal repair. We also evaluated patients with sporadic or
familial hypoplastic left heart syndrome (HLHS) after
discovering an individual with HLHS within one NKX2-5
mutant family.
METHODS
Patient recruitment. The study population comprised
consecutive individuals with secundum ASD or PFO who
underwent percutaneous closure at St. Vincent’s Hospital
(from 2000) and individuals identified retrospectively from
hospital records (St. Vincent’s and Sydney Children’s Hos-
pitals) in whom ASD closure had been performed (1982 to
1999). After identification of HLHS in one individual in
family 1024, a group of 18 HLHS individuals identified
prospectively through the Children’s Hospital-San Diego
and U.S. HLHS support groups was included. These
HLHS patients were karyotypically normal. Sequencing of
the connexin-43 gene, mutated in a subgroup of HLHS
patients (8), was not undertaken. Subjects were evaluated
clinically by taking a medical history and performing 12-
lead electrocardiography and transthoracic or transesopha-
geal echocardiography. A verbal family history was available
for all but 15 individuals. Informed, written consent was
obtained from all participants. The study protocol was
approved by institutional research ethics committees.
Molecular methods. The NKX2-5 locus was amplified
from 50 to 100 ng of blood genomic deoxyribonucleic acid
(DNA) using Expand Polymerase (according to the manu-
facturer’s instructions, Roche Applied Sciences, Basel, Swit-
zerland) and cycling conditions: 95°C, 2 min; 30 cycles of
94°C, 30 s; 68°C, 2 min. The polymerase chain reaction
(PCR) products were sequenced using the BigDye nucleo-
tide mix (according to the manufacturer’s instructions,
Applied Biosystems, California), ABI 3700 sequencer, and
Lasergene DNAstar (Wisconsin) software.
RESULTS
Clinical details. The NKX2-5 gene was sequenced in 102
ASD patients ascertained only because of their need for
ASD closure. Thirty-two patients were children (age range
birth to 14 years; mean 3.9 years) and 70 were adults (age
range 18 to 80 years; mean 44.7 years). Within the cohort,
four individuals (3.9%) also had first-degree AV conduction
block and 3 (2.9%) had some other form of CHD (Table 1).
Thirteen patients (10%) had a positive family history of
ASD, although no family members had evidence of AV
conduction block. Twenty-five PFO patients were also
assessed, because our previous studies in mice suggested that
ASD and PFO exist within a pathologic continuum (6).
The PFO cohort was drawn from patients with suspected
paradoxical embolism in whom PFO was subsequently
found. Thus, there is a likely selection bias toward more
severe PFO in this group (9).
Abbreviations and Acronyms
ASD  atrial septal defect
AV  atrioventricular
CHD  congenital heart disease
DNA  deoxyribonucleic acid
HLHS  hypoplastic left heart syndrome
PCR  polymerase chain reaction
PFO  patent foramen ovale
TOF  tetralogy of Fallot
Table 1. Patient Characteristics
ASD (n  102) PFO (n  25) HLHS (n  19*)
Male/female 37/65 12/13 11/8
Mean age in yrs (range)† 31.9 (birth to 80) 48.7 (12–73) 0.9 (birth to 4)
Positive family history‡ 12 1 12
AV conduction block† 4 1 0
Other cardiac conditions
Anomalous pulmonary venous drainage 2 0 0
Tricuspid annular dilation 1 0 0
Ebstein’s anomaly 0 0 0
Double-outlet right ventricle 0 0 2
Complete heterotaxy 0 0 1
NKX2-5 mutation 1§ 0 1§
*Includes one unaffected individual who was an obligate carrier of a familial mutation. †At the time blood was drawn. ‡First-
or second-degree relative with congenital heart disease; §both members of family 1024.
ASD  atrial septal defect; AV  atrioventricular; HLHS  hypoplastic left heart syndrome; PFO  patent foramen ovale.
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Molecular findings. Within the ASD/PFO cohort, only
one ASD patient with an NKX2-5 mutation was identified.
This individual had a normal electrocardiogram and a
positive family history (family1024; Fig. 1A). The proband’s
father (individual I-2) had an ASD complicated by episodes
of atrial and ventricular fibrillation, although it is unclear
whether these were primary or induced, because they
occurred postoperatively after surgical treatment for con-
strictive pericarditis and mitral valve ring implantation. He
had no evidence of AV conduction block. Individual II-1
had ASD in association with HLHS. Sequencing of
NKX2-5 revealed a heterozygous C-T transition at nucle-
otide 642 (GenBank AB021133), resulting in a T178M
amino acid change (Figs. 1A and 1C). This mutation
introduces a diagnostic NlaIII restriction enzyme cleavage
site, which was used to screen PCR-derived NKX2-5 DNA
of other family members (Fig. 1A). Cleavage was evident in
all affected members, including the individual with HLHS,
as well as in individual II-4, who was phenotypically normal.
As far as we are aware, this is the first documented case of
an NKX2-5 mutation correlating with HLHS. Hypoplastic
left heart syndrome is genetically heterogeneous and can be
associated with distal deletions of chromosome 11 as part of
Jacobsen syndrome (10), as well as in a subset of sporadic
cases with mutations in the connexin-43 gene (8). We
examined the NKX2-5 sequence from 18 additional patients
with sporadic or familial HLHS who had a normal karyo-
type, but no mutations were found. The T178M change
identified in this study was previously found in two ASD/
conduction disease families (3,5) and occurs within the
NKX2-5 homeodomain, thus severely diminishing its abil-
ity to bind DNA (7).
The other 12 individuals in our ASD/PFO cohort with a
positive family history did not carry NKX2-5 mutations.
This is consistent with findings that familial ASD is
genetically heterogeneous (11). The NKX2-5 family de-
scribed here differs from other mutant families reported in
the literature, all showing a combination of ASD and
high-grade AV conduction block. Only four patients in our
cohort had AV conduction block; these individuals did not
have a family history of CHD, and the conduction abnor-
mality was limited to first-degree AV block in all cases.
A second NKX2-5 amino acid change (E21Q) was
identified within a family with ASD but no conduction
disease (family AF1) (Fig. 1). However, evaluation of other
family members showed that that mutation did not segre-
gate with disease. This change has previously been reported
as pathogenic in one individual with TOF, although two
Figure 1. Families with atrial septal defect (ASD) and NKX2-5 changes. (A) Family 1024, showing ASD and hypoplastic left heart syndrome (HLHS).
NlaIII restriction enzyme analysis of polymerase chain reaction products (bottom) demonstrated that all affected and one unaffected individual (II-4) carried
the C642T mutation. Continued on next page.
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unaffected family members were also carriers (5). These
findings suggest that the amino acid change represents a
non-disease–causing polymorphism.
DISCUSSION
The T178M mutation and CHD. We found a single
individual within our cohort of 127 ASD/PFO patients who
carried a mutation in NKX2-5. This individual had a family
history of ASD without AV conduction block. The T178M
amino acid change in family 1024 is clearly pathogenic. The
change diminishes the ability of NKX2-5 to bind DNA (7)
and has been found in two other families showing highly
penetrant ASD and high-grade AV conduction disease (3).
The presence of an NKX2-5 mutation in a member of
family 1024 with HLHS raised the possibility that the
mutation may also cause this disorder. However, no muta-
tions were subsequently found in 18 individuals with HLHS
and a normal karyotype. Hypoplastic left heart syndrome is
believed to result from decreased flow to the left side of the
heart during ontogeny (10), and this could occur as a
consequence of haplo-insufficiency for NKX2-5 through the
effects on the conduction system (3,12) or left ventricular
development (13). Analysis of larger populations will be
required to confirm the suggested role for NKX2-5 muta-
tions in HLHS.
The penetrance of CHD in T178M families is high but
incomplete, as evidenced by the existence in family 1024 of
a child who was genotype-positive but phenotype-negative,
as assessed by transthoracic echocardiography with Doppler
Figure 1 Continued. (B) Family AF1, showing ASD over three generations. Among affected individuals genotyped (I-2, II-2, III-2), only III-2 carried the
C171G polymorphism. Sequence traces are shown. (C) Schematic representation of the NKX2-5 protein, showing functional domains and detected aa
changes. TN  TN domain; HD  homeodomain; NK2SD  NK2-specific domain.
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analysis. However, a small ASD or one that had closed
spontaneously earlier in life cannot be excluded. Further-
more, because the AV conduction block found in other
NKX2-5 mutant families is progressive, it is possible that
individuals from family 1024 are at risk of developing
late-onset conduction disease.
Implications for genetic causation in CHD. The princi-
pal conclusion of this study is that exonic NKX2-5 muta-
tions are a relatively infrequent cause of sporadic secundum
ASD. The single mutation detected in our ASD cohort
occurred in an individual with a family history of ASD;
none were found in 90 sporadic cases. Previous work has
associated NKX2-5 mutations with familial ASD and AV
conduction disease at a high penetrance, but also with a
spectrum of other abnormalities in families at a lower
penetrance. Hypoplastic left heart syndrome might now be
included in the growing list of defects attributable to
NKX2-5 mutation. Our studies also show that NKX2-5
mutations can occur in families in the absence of conduction
disease. These observations support a critical role for
NKX2-5 in diverse cardiac developmental processes.
The status of the E21Q change in family AF1 is unclear.
Although this polymorphism alters a conserved amino acid
within a known functional domain of NKX2-5 (TN do-
main) (Fig. 1C), it leads to a conservative substitution
(albeit one with an altered charge) and inserts glutamine
into an already glutamine-rich microenvironment. The
change has also been found in one TOF patient and
multiple unaffected members of the same family (5). In
family AF1, there was one ASD patient who carried the
change, but at least two members with ASD who did not,
clearly indicating that this change was not the disease-
causing mutation. We postulate that this polymorphism is,
in itself, unlikely to cause ASD, conduction disease, or
TOF, although a possible contribution to polygenic CHD
cannot be excluded.
Reprint requests and correspondence: Dr. Richard P. Harvey,
Victor Chang Cardiac Research Institute, 384 Victoria Street,
Darlinghurst 2010, Australia. E-mail: r.harvey@victorchang.
unsw.edu.au.
REFERENCES
1. Burn J, Goodship J. Congenital heart disease. In: Rimoin DL, Connor
JM, Pyeritz RE, editors. Emery and Rimoin’s Principals and Practice
of Medical Genetics. New York, NY: Churchill-Livingstone, 1996:
767–828.
2. Benson DW, Silberbach GM, Kavanaugh-McHugh A, et al. Muta-
tions in the cardiac transcription factor NKX2.5 affect diverse cardiac
developmental pathways. J Clin Invest 1999;104:1567–73.
3. Schott J-J, Benson DW, Basson CT, et al. Congenital heart disease
caused by mutations in the transcription factor NKX2-5. Science
1998;281:108–11.
4. Ikeda Y, Hiroi Y, Hosoda T, et al. Novel point mutation in the cardiac
transcription factor CSX/NKX2.5 associated with congenital heart
disease. Circ J 2002;66:561–3.
5. Goldmuntz E, Geiger E, Benson DW. NKX2.5 mutations in patients
with tetralogy of Fallot. Circulation 2001;104:2565–8.
6. Biben C, Weber R, Kesteven S, et al. Cardiac septal and valvular
dysmorphogenesis in mice heterozygous for mutations in the ho-
meobox gene Nkx2-5. Circ Res 2000;87:888–95.
7. Kasahara H, Lee B, Schott JJ, et al. Loss of function and inhibitory
effects of human CSX/NKX2.5 homeoprotein mutations associated
with congenital heart disease. J Clin Invest 2000;106:299–308.
8. Dasgupta C, Martinez A-M, Zuppan CW, Shah MM, Bailey LL,
Fletcher WH. Identification of connexin43 (1) gap junction muta-
tions in patients with hypoplastic left heart syndrome by denaturing
gradient gel electrophoresis (DGGE). Mutat Res 2001;479:173–86.
9. Schuchlenz HW, Weihs W, Horner S, Quehenberger F. The associ-
ation between the diameter of a patent foramen ovale and the risk of
embolic cerebrovascular events. Am J Med 2000;109:456–62.
10. Grossfeld PD, Rothman A, Gruber P, Chien KR. Molecular genetics
of congenital heart disease. In: Chien KR, editor. Molecular Basis of
Cardiovascular Disease: A Companion to Braunwald’s Heart Disease.
Philadelphia, PA: Saunders, 1999:135–65.
11. Benson DW, Sharkey A, Fatkin D, et al. Reduced penetrance, variable
expressivity, and genetic heterogeneity of familial atrial septal defects.
Circulation 1998;97:2043–8.
12. Kasahara H, Wakimoto H, Liu M, et al. Progressive atrioventricular
conduction defects and heart failure in mice expressing a mutant
Csx/Nkx2.5 homeoprotein. J Clin Invest 2001;108:189–201.
13. Biben C, Harvey RP. Homeodomain factor Nkx2-5 controls left-right
asymmetric expression of bHLH eHand during murine heart develop-
ment. Genes Dev 1997;11:1357–69.
2076 Elliott et al. JACC Vol. 41, No. 11, 2003
NKX2-5 Gene and CHD June 4, 2003:2072–6
